Related Experiment Video
Updated: Aug 19, 2026
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
Dynamic peripheral immune monitoring during checkpoint blockade: a framework for interpreting response, toxicity and
1Department of Oncology, the Fourth Affiliated Hospital of Soochow University, Medical Center of Soochow University, Suzhou Dushu Lake Hospital, Suzhou, Jiangsu, China.
Abstract:
Immune checkpoint inhibitors (ICIs) have reshaped cancer treatment, but their clinical benefit remains variable. Many patients show primary or acquired resistance, and immune-related adverse events (irAEs) can limit treatment or complicate clinical decisions. Tissue-based biomarkers have improved patient selection in selected settings. These include programmed death-ligand 1 (PD-L1) expression, tumor mutational burden, microsatellite instability/mismatch repair deficiency, tumor-infiltrating lymphocytes and T-cell-inflamed gene signatures. Yet these markers are mostly static and tumor-centered. They do not fully capture host immune competence, systemic inflammation, treatment-induced immune changes or toxicity-prone immune activation. Peripheral immune biomarkers may help address this gap. Blood-based markers are repeatable and can be assessed across treatment, making them useful for longitudinal monitoring during checkpoint blockade. In this review, we discuss peripheral biomarkers as dynamic readouts rather than isolated predictors of response, toxicity or resistance. For narrative synthesis, we group these signals into four heuristic interpretive patterns developed for this review rather than established biological states or clinically validated patient categories: immune-cold resistance, effective anti-tumor activation, toxicity-prone inflammatory amplification and inflamed but ineffective resistance. We review several layers of peripheral monitoring, including immune-cell dynamics, T-cell receptor repertoire changes, cytokine and chemokine networks, humoral signals, eosinophilic inflammation and circulating tumor burden markers. We discuss how these readouts can be interpreted across key clinical windows. These include baseline, early on-treatment assessment, first imaging, irAE onset, progression and rechallenge. Peripheral monitoring should complement tissue biomarkers, imaging and clinical judgment. Its clinical translation will require standardized sampling, assay harmonization, integrated interpretation and prospective validation.
Insights
Peripheral immune biomarkers offer dynamic insights into cancer treatment response and toxicity, complementing static tissue markers. Monitoring blood markers longitudinally helps predict outcomes and manage immune-related adverse events during therapy.
Area of Science:
- Oncology
- Immunology
- Biomarker Research
Background:
- Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but face challenges with variable patient response, resistance, and immune-related adverse events (irAEs).
- Current tissue-based biomarkers (e.g., PD-L1, TMB, MSI) are valuable but static and tumor-centric, failing to capture dynamic host immune status.
- A gap exists in understanding systemic immune changes, treatment effects, and toxicity predispositions during ICI therapy.
Purpose of the Study:
- To review the role of peripheral immune biomarkers as dynamic indicators of response, resistance, and toxicity in cancer patients treated with ICIs.
- To propose a framework for interpreting peripheral immune signals across different clinical time points.
- To highlight the potential of blood-based markers for longitudinal monitoring and personalized treatment strategies.
Main Methods:
- Narrative synthesis of existing literature on peripheral immune monitoring in ICI therapy.
- Categorization of peripheral immune signals into four heuristic interpretive patterns: immune-cold resistance, effective anti-tumor activation, toxicity-prone inflammatory amplification, and inflamed but ineffective resistance.
- Review of various peripheral monitoring layers including immune-cell dynamics, T-cell receptor repertoire, cytokine/chemokine networks, humoral signals, eosinophilic inflammation, and circulating tumor burden.
Main Results:
- Peripheral biomarkers provide dynamic readouts that complement static tissue markers, offering insights into host immune competence and treatment-induced changes.
- Interpreting these dynamic signals across key clinical windows (baseline, on-treatment, irAE onset, progression) can refine patient management.
- Four heuristic patterns aid in understanding complex immune responses and resistance mechanisms during ICI therapy.
Conclusions:
- Peripheral immune monitoring offers a dynamic, blood-based approach to complement tissue biomarkers, imaging, and clinical judgment in ICI therapy.
- Standardization of sampling, assay harmonization, integrated interpretation, and prospective validation are crucial for the clinical translation of peripheral biomarkers.
- Dynamic peripheral immune profiling holds promise for optimizing patient selection, predicting response, managing toxicity, and improving outcomes in cancer immunotherapy.
